| Literature DB >> 29664383 |
Regev Cohen, Frida Babushkin, Maurice Shapiro, Martina Uda, Yafit Atiya-Nasagi, Dar Klein, Talya Finn.
Abstract
We report a series of 5 case-patients who had Israeli spotted fever, of whom 2 had purpura fulminans and died. Four case-patients were given a diagnosis on the basis of PCR of skin biopsy specimens 3-4 days after treatment with doxycycline; 1 case-patient was given a diagnosis on the basis of seroconversion. Rickettsia spp. from the 2 case-patients who died were sequenced and identified as Rickettsia conorii subsp. israelensis. Purpura fulminans has been described in association with R. rickettsii and R. indica, but rarely with R. conorii subsp. israelensis.Entities:
Keywords: Israel; Israeli spotting fever; Rickettsia conorii subsp. israelensis; Sharon District; case series; purpura fulminans; rickettsia; vector-borne infections; zoonoses
Mesh:
Year: 2018 PMID: 29664383 PMCID: PMC5938761 DOI: 10.3201/eid2405.171992
Source DB: PubMed Journal: Emerg Infect Dis ISSN: 1080-6040 Impact factor: 6.883
Laboratory findings at hospitalization for 5 case-patients with Israeli spotted fever, Sharon District, Israel*
| Parameter | Reference range | Case-patient 1 | Case-patient 2 | Case-patient 3 | Case-patient 4 | Case-patient 5 |
|---|---|---|---|---|---|---|
| Leukocytes, cells/μL | 4,000–11,000 | 10,700 | 7,500 | 5,000 | 7,700 | 8,600 |
| PMNs, % | 40–75 | 87 | 86 | 81 | 85 | 91 |
| Platelets/μL | 150,000–400,000 | 37,000 | 73,000 | 91,000 | 75,000 | 139,000 |
| Sodium, mmol/L | 136–145 | 126 | 123 | 130 | 133 | 127 |
| Total bilirubin, mg/dL | 0.3–1.4 | 2.5 | 0.4 | 0.9 | 0.7 | 0.8 |
| AST, IU/L | 0–32 | 106 | 184 | 167 | 65 | 69 |
| ALT, IU/L | 0–33 | 51 | 154 | 139 | 68 | 66 |
| GGT, IU/L | 0–40 | 50 | 103 | 62 | 26 | 106 |
| LDH, IU/L | 240–480 | 1044 | 875 | 1195 | 466 | 536 |
| Creatinine, mg/dL | 0.5–0.9 | 1.7 | 1.4 | 1.0 | 1.4 | 1.0 |
| Creatine kinase, IU/L | 39–190 | 298 | 1933 | 152 | 159 | 100 |
| C-reactive protein, mg/L | 0–5 | 122 | 350 | 164 | 88 | 240 |
*ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, γ-glutamyl transferase; LDH, lactate dehydrogenase; PMN, polymorphonuclear leukocytes.
Clinical characteristics of 5 case-patients with Israeli spotted fever, Sharon District, Israel*
| Characteristic | Case-patient 1 | Case-patient 2 | Case-patient 3 | Case-patient 4 | Case-patient 5 |
|---|---|---|---|---|---|
| Age, y/sex | 75/F | 51/F | 38/ M | 48/M | 45/M |
| Concurrent condition | Hypertension | Mental retardation, diabetes mellitus | None | Alcoholism, HCV carrier, IVDU | Nephrolithiasis, psoriasis |
| Signs/symptoms at hospitalization | |||||
| Fever | Yes | Yes | Yes | Yes | Yes |
| Rash | Purpura fulminans | Maculopapular, then purpura fulminans | Maculopapular | Maculopapular | Maculopapular |
| Day of rash from disease onset | 6 | 6 | 4 | 4 | 3 |
| Hypotension | Yes | Yes | No | No | No |
| Multiorgan failure | Yes | Yes | No | No | No |
| Eschar | No | No | No | No | No |
| Headache | No | Unknown | Yes | No | No |
| Confusion | No | No | No | No | No |
| Myalgia | Yes | Unknown | Yes | No | No |
| Epidemiologic factor | |||||
| Animal exposure | Dog | Unknown | Dog | None | Dog |
| Tick exposure | No | No | No | No | No |
| Serologic result, day/result | |||||
| First sample | 9/nonreactive | 6/IgM titer >100, IgG titer borderline† | 6/nonreactive | 6/nonreactive | 5/nonreactive |
| Second sample | 19/IgM titer nonreactive, IgG titer 1:800† | NR | NR | NR | 19/IgM titer >1:100, IgG titer 1:1,600† |
| PCR result, whole blood/doxycycline treatment day | NR | +/3 | NR | NR | –/5 |
| PCR result, skin biopsy specimen/doxycycline treatment day | +/4 | +/3 | +/4 | +/3 | –/3 |
| Doxycycline treatment | |||||
| Day of illness | 6 | 5 | 5 | 5 | 4 |
| Day of hospitalization | 0 | 2 | 0 | 1 | 0 |
| Length of hospitalization, d | 14 | 20 | 7 | 4 | 8 |
| Outcome | Died | Died | Survived | Survived | Survived |
*HCV, hepatitis C virus; IVDU, intravenous drug use; NR, not relevant/not obtained; +, positive; –, negative. †Results from the Israeli reference laboratory for rickettsial diseases.
Figure 1Case-patient 1, a 75-year-old woman with Israeli spotted fever and purpura fulminans, Sharon District, Israel, 3 days after hospitalization. Diffuse fern-leaf pattern of purpura and newly formed bulla on the legs are shown.
Figure 2Case-patient 1, a 75-year-old woman with Israeli spotted fever and purpura fulminans, Sharon District, Israel, 7 days after hospitalization. A rash on the legs that had become bullous and contained clear serous fluid is shown.
Figure 3Case-patient 1, a 75-year-old woman with Israeli spotted fever and purpura fulminans, Sharon District, Israel, 14 days after hospitalization. Dusky skin lesions on the legs, necrosis at the extremities, and extensive desquamation are shown.